KRAS and neoplasm: Sensitivity to CTL lysis was enhanced in prostate, breast, and lung tumor cells regardless of their p53, triple-negative, or K-Ras mutational status, respectively (Table 1), suggesting that 223Ra may be used to effectively treat bone metastases arising from each of these tumor types.